- Home
- SCSC vs ANAB Comparison
SCSC vs ANAB Comparison
Compare SCSC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCSC
- ANAB
- Stock Information
- Founded
- SCSC 1992
- ANAB 2005
- Country
- SCSC United States
- ANAB United States
- Employees
- SCSC N/A
- ANAB N/A
- Industry
- SCSC Retail: Computer Software & Peripheral Equipment
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- SCSC Technology
- ANAB Health Care
- Exchange
- SCSC Nasdaq
- ANAB Nasdaq
- Market Cap
- SCSC 892.3M
- ANAB 951.1M
- IPO Year
- SCSC 1994
- ANAB 2017
- Fundamental
- Price
- SCSC $42.25
- ANAB $36.58
- Analyst Decision
- SCSC Hold
- ANAB Buy
- Analyst Count
- SCSC 1
- ANAB 11
- Target Price
- SCSC $43.00
- ANAB $57.00
- AVG Volume (30 Days)
- SCSC 141.9K
- ANAB 558.3K
- Earning Date
- SCSC 11-06-2025
- ANAB 10-31-2025
- Dividend Yield
- SCSC N/A
- ANAB N/A
- EPS Growth
- SCSC N/A
- ANAB N/A
- EPS
- SCSC 3.00
- ANAB N/A
- Revenue
- SCSC $3,040,810,000.00
- ANAB $123,164,000.00
- Revenue This Year
- SCSC $6.68
- ANAB $24.36
- Revenue Next Year
- SCSC $4.22
- ANAB N/A
- P/E Ratio
- SCSC $14.13
- ANAB N/A
- Revenue Growth
- SCSC N/A
- ANAB 304.17
- 52 Week Low
- SCSC $28.75
- ANAB $12.21
- 52 Week High
- SCSC $53.90
- ANAB $36.70
- Technical
- Relative Strength Index (RSI)
- SCSC 46.10
- ANAB 74.26
- Support Level
- SCSC $42.03
- ANAB $33.01
- Resistance Level
- SCSC $43.50
- ANAB $36.70
- Average True Range (ATR)
- SCSC 0.96
- ANAB 1.55
- MACD
- SCSC 0.05
- ANAB -0.00
- Stochastic Oscillator
- SCSC 55.66
- ANAB 97.83
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).